Xtant Medical Reports Third Quarter 2026 Financial Results and Announces Board-led Strategic Review Process

BELGRADE, Mont., Nov. 16, 2026 /PRNewswire/ — Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today reported financial and operating results for the third quarter ended September 30, 2026.

Third Quarter 2026 Financial Highlights

  • Total revenue was $24.3 million for the third quarter of 2026, compared to $33.3 million for the third quarter of 2025 and up 5% from $23.0 million in the second quarter of 2026. The year-over-year decrease primarily reflects the absence of revenue from divested businesses and wound care licensing revenue.
  • Biologics revenue was $19.3 million for the third quarter of 2026, up 13% from the third quarter of 2025 and up 11% from the second quarter of 2026, third quarter 2026 revenue includes $2.2 million from sales of HEMOBLAST® Bellows.

“The Board is disappointed with Xtant’s financial performance this quarter, which marks the second consecutive quarter in which our results have not met our guidance. That is unacceptable,” said Stavros Vizirgianakis, Chairman of the Board. “Certain directors, including me, have invested their own capital in Xtant, and the Board includes a representative of our largest stockholder. The Board feels this shortfall as owners and stewards of the Company, not just as directors, and the Board’s interests are directly aligned with stockholders. The Board’s priorities are clear: improve execution, improve financial performance, and maximize stockholder value through the strategic review process. Already we are encouraged by how our core biologics business is gaining momentum both quarter-over-quarter and year-over-year.”

The Board’s active strategic review process is evaluating a broad range of potential actions to maximize stockholder value, which may include, among other things, operational and performance improvement initiatives, capital allocation and capital structure alternatives, commercial or strategic partnerships, restructurings, financings, acquisitions, dispositions, business combinations or other transactions. The Board has not set a timetable for completion of the strategic review process, and there can be no assurance that the process will result in any particular action or outcome. The Company does not intend to disclose further developments unless and until the Board approves a specific action or otherwise determines that further disclosure is appropriate or required.

Third Quarter 2026 Financial Results

Revenue for the third quarter of 2026 was $24.3 million compared to $33.3 million for the third quarter of 2025 and up 5% from $23.0 million in the second quarter of 2026. The year-over-year decrease primarily reflects the absence of $5.4 million of prior-year revenue from the divested non-core Coflex/CoFix assets and international hardware business, and the absence of $5.5 million of prior-year wound care licensing revenue, partially offset by $2.2 million of HEMOBLAST revenue. Biologics revenue was $19.3 million, an increase of 13% from $17.1 million for the third quarter of 2025 and 11% from $17.4 million for the second quarter of 2026. Biologics product revenue excluding HEMOBLAST and products affected by the market for wound care reimbursement, a non-GAAP measure, grew 8% compared to the second quarter of 2026 and 6% compared to the third quarter of 2025.

Gross margin for the third quarter of 2026 was 56.3%, compared to 66.1% for the same period in 2025. The decrease primarily reflected a 670-basis-point impact from the cessation of high-margin wound care licensing revenue and a 360-basis-point impact from sales mix.

Operating expenses for the third quarter of 2026 were $16.7 million, compared to $19.5 million for the third quarter of 2025. General and administrative expenses decreased to $5.0 million from $7.1 million, due primarily to the divested non-core Coflex/CoFix assets and international hardware business and lower expense under compensation plans. Sales and marketing expenses decreased to $11.2 million from $11.7 million due primarily to savings related to the divestitures and lower consulting fees, partially offset by higher compensation expense from increased sales headcount, including sales personnel hired in connection with the Company’s exclusive U.S. distribution agreement for HEMOBLAST, and by higher independent agent commissions and travel expenses.

Net loss for the third quarter of 2026 was $3.6 million, or $0.03 per share, compared to net income of $1.3 million, or $0.01 per diluted share, for the third quarter of 2025.

Adjusted EBITDA, a non-GAAP measure, was a loss of $1.5 million for the third quarter of 2026, compared to adjusted EBITDA of $4.5 million for the third quarter of 2025.

The Company defines adjusted EBITDA as net income/loss from operations before depreciation, amortization and interest income/expense and provision for income tax/benefit, and as further adjusted to add back in or exclude, as applicable, non-cash compensation, the write-off of the distribution agreement deposit, disposition/ acquisition-related income and expenses, acquisition-related fair value adjustments, unrealized foreign currency translation gain or loss, and separation-related expenses. A calculation and reconciliation of adjusted EBITDA to net income (loss) is included in the financial tables at the end of this release.

As of September 30, 2026, the Company had $7.8 million of cash and cash equivalents; $22 million of total indebtedness, consisting of $10.2 million of current and long-term debt and $11.8 million of borrowings under its revolving credit facility; and $2.1 million of availability under its revolving credit facility. As of December 31, 2025, the Company had $17.1 million of cash and cash equivalents; $25.4 million of total indebtedness, consisting of $14.5 million of current and long-term debt and $10.9 million of revolving credit borrowings; and $3.8 million of revolving credit availability.

Based on its current operating plan, the Company expects its cash and cash equivalents, and availability under its revolving credit facility, to be sufficient to fund operations for at least the next 12 months.

2026 Financial Guidance

Based on year-to-date performance, the Company no longer expects to achieve its previously issued full-year 2026 guidance. While the Board of Directors conducts its strategic review process, the Company is not providing revised full-year 2026 financial guidance. At the same time, as detailed elsewhere in this release, the Board is encouraged by the recent momentum in the Company’s core biologics business and remains committed to scaling this franchise throughout the strategic review process.

Conference Call

Xtant Medical will not host a conference call or webcast to discuss its third quarter 2026 financial results. 

About Xtant Medical Holdings, Inc.

Xtant Medical’s mission of honoring the gift of donation so that our patients can live as full and complete a life as possible, is the driving force behind our company. Xtant Medical Holdings, Inc. (www.xtantmedical.com) is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics serving the chronic and surgical wound care and sports medicine markets, as well as spinal implant systems. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.

The symbols ™ and ® denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in the United States, and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.

Non-GAAP Financial Measures

To supplement the Company’s consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses certain non-GAAP financial measures in this release, including EBITDA, adjusted EBITDA, EBITDA and adjusted EBITDA as a percentage of total revenue, and biologics product revenue excluding HEMOBLAST and products affected by the market for wound care reimbursement. Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures are included in the tables at the end of this release. The Company’s management believes that the presentation of these measures provides useful information to investors. These measures may assist investors in evaluating the Company’s operations period over period. Management uses the non-GAAP measures in this release internally for evaluation of the performance of the business, including the allocation of resources. Investors should consider non-GAAP financial measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as “intends,” “expects,” “anticipates,” “plans,” “believes,” “estimates,” “projects,” “seeks,” “aims,” “goal,” “strategy,” “continue,” “future,” “will,” “would,” “should,” “could,” “may,” “potential,” “opportunity,” “guidance,” similar expressions or the negative thereof, and the use of future dates. Forward-looking statements in this release include, among others, statements regarding the recent momentum in the Company’s core biologics products business and the Board’s commitment to scaling that business; the Board’s priorities to improve execution, improve financial performance, and maximize stockholder value through the strategic review process; the scope, timing, conduct and potential outcomes of the strategic review process; the Company’s expectation that it will not achieve its previously issued full-year 2026 guidance; the Company’s expectation that its cash and cash equivalents and availability under its revolving credit facility, will be sufficient to fund operations for at least the next 12 months; and the expected timing of the filing of the Company’s Quarterly Report on Form 10-Q. The Company cautions that its forward-looking statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the Company’s future operating results, financial performance and need for additional capital; the Company’s ability to sustain or increase revenue growth in its biologics business, including the possibility that recent growth trends will not continue; results of the Board’s strategic review process, including the possibility that the process will not result in any strategic alternative, operational change, restructuring, transaction, initiative or other action, or that any action taken will not achieve its anticipated benefits or enhance stockholder value; the timing of the strategic review process and the possibility that it may be suspended, modified or terminated at any time; the Company’s ability to identify, negotiate, finance, obtain any required approvals for and complete any strategic alternative, operational change, transaction, partnership, restructuring or other action on favorable terms or at all, and to implement successfully its strategic priorities to improve execution, improve financial performance, and maximize stockholder value through the strategic review process; risks associated with the strategic review process, including disruption and distraction of management, costs, and effects on employees, agents, customers, suppliers and other business relationships; the absence of financial guidance and the Company’s inability to achieve its previously issued guidance; the Company’s ability to generate operating cash flows and maintain availability under its revolving credit facility; the success of the Dilon distribution arrangement and the HEMOBLAST product and the possibility that the distribution agreement may be terminated and the effect of any such termination on the Company, its business and operating results; the ability of Dilon to continue to manufacture and supply the HEMOBLAST product and the effect of any such non-performance on the Company and its business and operating results; the success of the Company’s expanded field sales force to improve its reach and leverage its contract portfolio and independent agent network; other risks associated with acquisitions and dispositions; possible future impairment charges to long-lived assets and goodwill and write-downs of excess and obsolete inventory; its ability to continue to innovate, develop and introduce new products and the success of those products; its ability to remain competitive; its ability to engage and retain new and existing independent distributors and agents and qualified sales and other personnel and its dependence on key independent agents for a significant portion of its revenue; the effect of inflation, elevated interest rates and other recessionary factors and supply chain disruptions; the effect of product sales mix changes on its financial results; the effect of government and third-party coverage and reimbursement for its products, including the absence of future license revenue resulting from changes in the reimbursement environment; its ability to obtain and maintain regulatory approvals and comply with government regulations; the effect of product liability claims and other litigation to which the Company may be subject, including any litigation relating to the strategic review process; the effect of product recalls and defects; its ability to obtain and protect its intellectual property and proprietary rights and operate without infringing the rights of others; its ability to service its debt and comply with the covenants in its credit agreements, including the minimum liquidity and net revenue covenants, to obtain any needed future amendments or waivers, and to access additional indebtedness or financing on favorable terms or at all, if and when needed; and other factors described in its Annual Report on Form 10-K for the year ended December 31, 2025 filed with the Securities and Exchange Commission (SEC) on March 30, 2026 and subsequent SEC reports, including its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2026 to be filed with the SEC on or about November 16, 2026. Investors are encouraged to read the Company’s filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by this cautionary statement.

XTANT MEDICAL HOLDINGS, INC.Consolidated Balance Sheets(In thousands, except number of shares and par value)
As of
September 30, 2026
As of December 31, 2025
(Unaudited)
ASSETS
Current Assets:
Cash and cash equivalents$7,793$17,053
Restricted cash92275
Trade accounts receivable, net of allowance for credit losses and 
doubtful accounts of $2,756 and $2,165, respectively
18,82317,803
Inventories32,50330,263
Note receivable—10,462
Prepaid and other current assets1,3952,389
Total current assets60,60678,245
Property and equipment, net5,4496,202
Right-of-use asset, net2,7383,192
Goodwill6,0746,074
Intangible assets, net229299
Other assets127133
Total Assets$75,223$94,145
LIABILITIES & STOCKHOLDERS’ EQUITY
Current Liabilities:
Accounts payable$5,364$3,844
Accrued liabilities7,69910,626
Current portion of long-term debt4,7703,500
Current portion of lease liability588622
Current portion of finance lease obligations1935
Line of credit11,83310,857
Total current liabilities30,27329,484
Long-term Liabilities:
Lease liability, less current portion2,2482,665
Finance lease obligation, less current portion—12
Long-term debt, plus premium and less issuance costs5,43611,026
Other liabilities75
Total Liabilities37,96443,192
Commitments and Contingencies
Stockholders’ Equity:
Preferred stock, $0.000001 par value; 10,000,000 shares 
authorized; no shares issued and outstanding
——
Common stock, $0.000001 par value; 300,000,000 shares 
authorized; 140,452,061 shares issued and outstanding as of 
September 30, 2026 and 140,039,557 shares issued and 
outstanding as of December 31, 2025
——
Additional paid-in capital307,810305,439
Accumulated other comprehensive loss(1)—
Accumulated deficit(270,550)(254,486)
Total Stockholders’ Equity37,25950,953
Total Liabilities & Stockholders’ Equity$75,223$94,145
XTANT MEDICAL HOLDINGS, INC.Consolidated Statements of Operations(Unaudited, in thousands, except number of shares and per share amounts)
Three Months EndedSeptember 30,Nine Months EndedSeptember 30,
2026202520262025
Revenue
Product revenue$24,285$27,772$68,200$87,492
License revenue—5,483—14,078
Total Revenue24,28533,25568,200101,570
Cost of Sales10,62311,26329,23735,051
Gross Profit13,66221,99238,96366,519
Operating Expenses
General and administrative5,0137,07117,72222,082
Sales and marketing11,18111,74629,73534,566
Research and development4966341,6261,643
Write-off of distribution agreement deposit——5,000—
Total Operating Expenses16,69019,45154,08358,291
(Loss) Income from Operations(3,028)2,541(15,120)8,228
Other Expense
Interest expense(590)(904)(1,731)(2,953)
Interest income——220—
Unrealized foreign currency transaction 
(loss) gain 
(10)(56)12146
Other income (expense)231(16)820(18)
Total Other Expense(369)(976)(679)(2,825)
Net (Loss) Income from Operations 
Before Provision for Income Taxes
(3,397)1,565(15,799)5,403
Provision for Income Taxes Current and 
Deferred
(165)(257)(265)(487)
Net (Loss) Income$(3,562)$1,308$(16,064)$4,916
Net (Loss) Income Per Share:
Basic$(0.03)$0.01$(0.11)$0.04
Diluted$(0.03)$0.01$(0.11)$0.03
Shares used in the computation:
Basic140,363,595139,712,969140,228,117139,366,489
Diluted140,363,595150,377,234140,228,117149,912,292
XTANT MEDICAL HOLDINGS, INC.Consolidated Statements of Cash Flows(Unaudited, in thousands)
Nine Months Ended
September 30,
20262025
Operating activities:
Net (loss) income$(16,064)$4,916
Adjustments to reconcile net (loss) income to net cash (used in) provided by 
operating activities:
Depreciation and amortization1,5253,404
Loss (gain) on sale of fixed assets—(16)
Non-cash interest380415
Stock-based compensation2,4512,165
Provision for reserve on accounts receivable987568
Provision for excess and obsolete inventory2,9041,318
Write-off of distribution agreement deposit5,000—
Other468
Changes in operating assets and liabilities:
Accounts receivable(2,007)(5,639)
Inventories(4,215)(2,789)
Prepaid and other assets166314
Accounts payable1,519(1,279)
Accrued liabilities(2,927)3,721
Net cash (used in) provided by operating activities(10,277)7,166
Investing activities:
Purchases of property and equipment(830)(1,987)
Proceeds from sale of fixed assets129206
Distribution agreement deposit(5,000)—
Proceeds from divestitures10,3685,000
Net cash provided by investing activities4,6673,219
Financing activities:
Borrowings on line of credit51,87977,573
Repayments on line of credit(50,902)(78,385)
Payments on long-term debt(4,701)(5,000)
Debt issuance costs—(49)
Payments on financing leases(27)(51)
Payment of taxes from withholding of common stock on settlement of restricted 
stock units
(80)(116)
Net cash used in financing activities(3,831)(6,028)
Effect of exchange rate changes on cash and cash equivalents and restricted cash(2)63
Net change in cash and cash equivalents and restricted cash(9,443)4,420
Cash and cash equivalents and restricted cash at beginning of period17,3286,221
Cash and cash equivalents and restricted cash at end of period$7,885$10,641
Reconciliation of cash and cash equivalents and restricted cash reported in the 
condensed consolidated balance sheets
Cash and cash equivalents$7,793$10,400
Restricted cash92241
Total cash and restricted cash reported in condensed consolidated balance sheets$7,885$10,641
XTANT MEDICAL HOLDINGS, INC.CALCULATION OF NON-GAAP CONSOLIDATED EBITDA AND ADJUSTED EBITDA (in thousands)
Three Months EndedSeptember 30,Nine Months EndedSeptember 30,
2026202520262025
Net (Loss) Income$(3,562)$1,308$(16,064)$4,916
   Depreciation and amortization4831,1611,5253,404
   Interest expense, net5909041,5112,953
   Tax expense165257265487
   Non-GAAP EBITDA(2,324)3,630(12,763)11,760
   Net (Loss) Income/Total Revenue(14.7)%3.9%(23.6)%4.8%
   Non-GAAP EBITDA/Total Revenue(9.6)%10.9%(18.7)%11.6%
NON-GAAP ADJUSTED EBITDA CALCULATION
   Non-cash compensation8306412,4512,165
   Write-off of distribution agreement deposit——5,000—
   Divestiture/acquisition-related expenses(94)74(612)369
   Acquisition-related fair value adjustments37140132311
   Unrealized foreign currency translation loss (gain)1056(12)(146)
   Separation related expenses69—6923
   Non-GAAP Adjusted EBITDA$(1,472)$4,541$(5,735)$14,482
   Non-GAAP Adjusted EBITDA/Total 
Revenue
(6.1)%13.7%(8.4)%14.3%
XTANT MEDICAL HOLDINGS, INC.RECONCILIATION OF NON-GAAP BIOLOGICS PRODUCT REVENUE GROWTH(in thousands)
Three Months Ended
 September 30, 
2026
June 30,2026% Increase 
(Decrease)
   Total Revenue$24,285$23,031
License Revenue——
Hardware Revenue4,9445,671
   Biologics Revenue19,34117,360
Sales related to HEMOBLAST and products affected by the 
market for wound care reimbursement
2,2041,518
Biologics product revenue excluding HEMOBLAST and 
products affected by the market for wound care reimbursement
$17,137$15,8428%
Three Months Ended
 September 30, 
2026
September 30, 
2025
% Increase 
(Decrease)
   Total Revenue$24,285$33,255
License Revenue—5,483
Hardware Revenue4,94410,623
   Biologics Revenue19,34117,149
Sales related to HEMOBLAST and products affected by the 
market for wound care reimbursement
2,204935
Biologics product revenue excluding HEMOBLAST and 
products affected by the market for wound care reimbursement
$17,137$16,2146%

SOURCE Xtant Medical Holdings, Inc.

Keep Up to Date with the Most Important News

By pressing the Subscribe button, you confirm that you have read and are agreeing to our Privacy Policy and Terms of Use